Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 9% Improvement Relative Risk c19hcq.org Fitzgerald et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 4,666 patients in the USA No significant difference in cases Fitzgerald et al., medRxiv, doi:10.1101/2021.02.03.21251069 Favors HCQ Favors control
Risk Factors for Infection and Health Impacts of the COVID-19 Pandemic in People with Autoimmune Diseases
Fitzgerald et al., medRxiv, doi:10.1101/2021.02.03.21251069 (Preprint)
Fitzgerald et al., Risk Factors for Infection and Health Impacts of the COVID-19 Pandemic in People with Autoimmune Diseases, medRxiv, doi:10.1101/2021.02.03.21251069 (Preprint)
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 4666 people with autoimmune or inflammatory conditions, showing HCQ adjusted risk of COVID-19 OR 0.91 [0.68-1.23]. Results are not adjusted for the significantly different risk of COVID-19 depending on the type and severity of autoimmune or inflammatory condition. This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the baseline risk differences within systemic autoimmune patients.
risk of case, 8.5% lower, RR 0.91, p = 0.54, treatment 65 of 1,072 (6.1%), control 200 of 3,594 (5.6%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fitzgerald et al., 5 Feb 2021, retrospective, USA, preprint, 34 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.02.03.21251069; this version posted February 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Fitzgerald et al. 1 RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES Kathryn C. Fitzgerald1,2, ScD, Christopher A. Mecoli3, MD, MHS, Morgan Douglas1, BS, Samantha Harris1, BS, Berna Aravidis1, BS, Jemima Albayda3, MD, Elias S. Sotirchos1, MD, Ahmet Hoke1, MD, PhD, AnaMaria Orbai3, MD, MHS, Michelle Petri1, MD, MPH, Lisa Christopher-Stine3, MD, Alan N. Baer, MD3, Julie J. Paik3, MD, MHS, Brittany L. Adler3, MD, Eleni Tiniakou3, MD, Homa Timlin3, MD, MSc, Pavan Bhargava1, MD, Scott D. Newsome1, DO, Arun Venkatesan1, MD, PhD, Vinay Chaudhry1, MD, Thomas E. Lloyd1, MD, PhD, Carlos A. Pardo1, MD, Barney J. Stern1, MD, Mark Lazarev4, MD, Brindusa Truta4, MD, MAS, Shiv Saidha1, MBBCh, Edward S. Chen5, MD, Michelle Sharp5, MD, MHS, Nisha Gilotra6, MD, Edward K. Kasper6, MD, Allan C. Gelber, MD, MPH, PhD2,3, Clifton O. Bingham III3, MD, Ami A. Shah3, MD, MHS, Ellen M. Mowry1,2, MD, MCR 1 Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 3 Division of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA 4 Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA 5 Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA 6 Department of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA 2 Title: 105 characters Abstract: 275 words Text: 3591 References: 30 Tables: 4 Figures: 2 eTables: 8 Author Email Addresses: fitzgerald@jhmi.edu cmecoli1@jhmi.edu mdougl18@jhmi.edu sharr141@jhmi.edu baravid1@jhmi.edu jalbayd1@jhmi.edu ahoke@jhmi.edu ess@jhmi.edu aorbai1@jhmi.edu mpetri@jhmi.edu lchrist4@jhmi.edu alanbaer@jhmi.edu jpaik1@jhmi.edu brit.adler@jhmi.edu NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.02.03.21251069; this version posted February 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Fitzgerald et al. 2 etiniak1@jhmi.edu htimlin1@jhmi.edu pbharga2@jhmi.edu snewsom2@jhmi.edu avenkat2@jhmi.edu vchaudh@jhmi.edu tlloyd4@jhmi.edu cpardov1@jhmi.edu bstern6@jhmi.edu mlazare1@jhmi.edu btruta1@jhmi.edu ssaidha2@jhmi.edu chenedwa@jhmi.edu msharp5@jhmi.edu naggarw2@jhmi.edu ekasper@jhmi.edu agelber@jhmi.edu cbingha2@jhmi.edu ami.shah@jhmi.edu emowry1@jhmi.edu Corresponding author: Kathryn C Fitzgerald fitzgerald@jhmi.edu 600 N Wolfe St Pathology 627 Baltimore MD, 21287 medRxiv preprint doi: https://doi.org/10.1101/2021.02.03.21251069; this version posted February 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit